Cargando…

CircRERE confers the resistance of multiple myeloma to bortezomib depending on the regulation of CD47 by exerting the sponge effect on miR-152-3p

BACKGROUND: Inevitable resistance to chemotherapeutic drugs has become a major obstacle for the clinical treatment of multiple myeloma (MM). Circular RNAs (circRNAs) can regulate the chemoresistance in different tumors. Our study was to explore the regulation of circRNA arginine-glutamic acid dipept...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Wei, Mu, Jiao, Yang, Yi, Liu, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283016/ https://www.ncbi.nlm.nih.gov/pubmed/34307012 http://dx.doi.org/10.1016/j.jbo.2021.100381

Ejemplares similares

A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
por: Ding, Nan, et al.
Publicado: (2023)

N(6) ‐methyladenosine‐modified circRNA RERE modulates osteoarthritis by regulating β‐catenin ubiquitination and degradation
por: Liu, Yuxi, et al.
Publicado: (2022)

CircRNA RERE Promotes the Oxidative Stress-Induced Apoptosis and Autophagy of Nucleus Pulposus Cells through the miR-299-5p/Galectin-3 Axis
por: Wang, Rong, et al.
Publicado: (2021)

Retracted: CircRNA RERE Promotes the Oxidative Stress-Induced Apoptosis and Autophagy of Nucleus Pulposus Cells through the miR-299-5p/Galectin-3 Axis
por: Healthcare Engineering, Journal of
Publicado: (2022)

Circulating Exosomal CircMYC Is Associated with Recurrence and Bortezomib Resistance in Patients with Multiple Myeloma
por: Luo, Yanwei, et al.
Publicado: (2020)

Circular RNA hsa_circ_0076690 acts as a prognostic biomarker in osteoporosis and regulates osteogenic differentiation of hBMSCs via sponging miR-152
por: Han, Shijie, et al.
Publicado: (2020)

Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity
por: Ramji, Kavita, et al.
Publicado: (2022)

Mouse Model Reveals the Role of RERE in Cerebellar Foliation and the Migration and Maturation of Purkinje Cells
por: Kim, Bum Jun, et al.
Publicado: (2014)

RERE deficiency leads to decreased expression of GATA4 and the development of ventricular septal defects
por: Kim, Bum Jun, et al.
Publicado: (2018)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

CircATRNL1 and circZNF608 Inhibit Ovarian Cancer by Sequestering miR-152-5p and Encoding Protein
por: Lyu, Mengmeng, et al.
Publicado: (2022)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Familial intracranial arachnoid cysts with a missense mutation (c.2576C > T) in RERE: A case report
por: Wang, Yubo, et al.
Publicado: (2018)

CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7
por: Zeng, Kaixuan, et al.
Publicado: (2018)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

CircNRIP1 Exerts Oncogenic Functions in Papillary Thyroid Carcinoma by Sponging miR-653-5p and Regulating PBX3 Expression
por: Fu, Lijun, et al.
Publicado: (2022)

Long non-coding RNA EWSAT1 contributes to the proliferation and invasion of glioma by sponging miR-152-3p
por: Yang, Hui, et al.
Publicado: (2020)

circHLA-C Plays an Important Role in Lupus Nephritis by Sponging miR-150
por: Luan, Junjun, et al.
Publicado: (2017)

LINC00210 exerts oncogenic roles in glioma by sponging miR-328
por: Wang, Zhifei, et al.
Publicado: (2020)

Down-Regulation of CD9 by Methylation Decreased Bortezomib Sensitivity in Multiple Myeloma
por: Hu, Xiaotong, et al.
Publicado: (2014)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020)

circNFIC suppresses breast cancer progression by sponging miR-658
por: Xu, Gaosheng, et al.
Publicado: (2020)

Circ_0005918 Sponges miR-622 to Aggravate Intervertebral Disc Degeneration
por: Cui, Yan, et al.
Publicado: (2022)

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma
por: Amodio, Nicola, et al.
Publicado: (2019)

Long Noncoding RNA HAGLROS Promotes Cell Invasion and Metastasis by Sponging miR-152 and Upregulating ROCK1 Expression in Osteosarcoma
por: Zhou, Kaifeng, et al.
Publicado: (2020)

An Allelic Series of Mice Reveals a Role for RERE in the Development of Multiple Organs Affected in Chromosome 1p36 Deletions
por: Kim, Bum Jun, et al.
Publicado: (2013)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iq503gfre3v4i08vdl2vcq49mk